CytomX Therapeutics Inc (NASDAQ: CTMX) flaunted slowness of -5.38% at $1.76, before settling in for the price of $1.86 at the close. Taking a more long-term approach, CTMX posted a 52-week range of $1.04-$2.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 28.25%. Meanwhile, its Annual Earning per share during the time was 67.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -3067.00%. This publicly-traded company’s shares outstanding now amounts to $67.31 million, simultaneously with a float of $66.42 million. The organization now has a market capitalization sitting at $119.19 million. At the time of writing, stock’s 50-day Moving Average stood at $2.0182, while the 200-day Moving Average is $1.6062.
CytomX Therapeutics Inc (CTMX) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the CytomX Therapeutics Inc industry. CytomX Therapeutics Inc’s current insider ownership accounts for 1.92%, in contrast to 48.30% institutional ownership. According to the most recent insider trade that took place on Mar 19 ’24, this organization’s CEO sold 20,223 shares at the rate of 2.09, making the entire transaction reach 42,175 in total value, affecting insider ownership by 524,481. Preceding that transaction, on Mar 19 ’24, Company’s SVP, Chief Scientific Officer sold 12,795 for 2.09, making the whole transaction’s value amount to 26,684. This particular insider is now the holder of 168,579 in total.
CytomX Therapeutics Inc (CTMX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.22 per share during the current fiscal year.
CytomX Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -3067.00% and is forecasted to reach -0.37 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -0.90% through the next 5 years, which can be compared against the 67.21% growth it accomplished over the previous five years trading on the market.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Let’s observe the current performance indicators for CytomX Therapeutics Inc (CTMX). It’s Quick Ratio in the last reported quarter now stands at 1.17. The Stock has managed to achieve an average true range (ATR) of 0.15. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.18.
In the same vein, CTMX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.02, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.37 at the market close of one year from today.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Now, what If we examine the latest scores posted by [CytomX Therapeutics Inc, CTMX]. During the last 5-days, its volume was lower the volume of 0.87 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 42.03% While, its Average True Range was 0.1444.
Raw Stochastic average of CytomX Therapeutics Inc (CTMX) in the period of the previous 100 days is set at 33.03%, which indicates a major rise in contrast to 0.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 50.28% that was lower than 79.67% volatility it exhibited in the past 100-days period.
